<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01012661</url>
  </required_header>
  <id_info>
    <org_study_id>P0408329</org_study_id>
    <nct_id>NCT01012661</nct_id>
  </id_info>
  <brief_title>Evaluation of Pain With Lidocaine-Mixed Radiesse® Injectable Dermal Filler</brief_title>
  <official_title>Evaluation of Pain With the Use of Lidocaine-Mixed Radiesse® Injectable Dermal Filler for the Treatment of Nasolabial Folds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz North America, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess pain during nasolabial fold treatment using Radiesse® Injectable Dermal Filler
      mixed with lidocaine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess pain immediately after nasolabial fold treatment with Radiesse® Injectable Dermal
      Filler mixed with lidocaine in one nasolabial fold compared to Radiesse® Injectable Dermal
      Filler without lidocaine in the contralateral nasolabial fold.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain)</measure>
    <time_frame>Immediately after injection (Time 0)</time_frame>
    <description>Assessment of difference in pain score in the Radiesse Dermal Filler Mixed with Lidocaine nasolabial fold v. the Radiesse Dermal Filler without Lidocaine nasolabial fold using a 10-cm visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patients With Clinically Significant Reduction in Pain</measure>
    <time_frame>Immediately after injection (Time 0)</time_frame>
    <description>Assessment of clinical significance of pain reduction in the Radiesse Injectable Dermal Filler Mixed with Lidocaine nasolabial fold v. Radiesse Injectable Dermal Filler without Lidocaine nasolabial fold defined as number of participants with &gt;/= 2cm difference on a visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Nasolabial Folds</condition>
  <arm_group>
    <arm_group_label>Radiesse® Mixed with Lidocaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiesse® without Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Injectable Dermal Filler. The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse® Injectable Dermal Filler Mixed with Lidocaine</intervention_name>
    <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)</description>
    <arm_group_label>Radiesse® Mixed with Lidocaine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Radiesse® Injectable Dermal Filler without Lidocaine</intervention_name>
    <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)</description>
    <arm_group_label>Radiesse® without Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Is at least 18 years of age.

          -  Is a candidate for nasolabial fold treatment using Radiesse.

          -  Understands and accepts the obligation not to receive any other facial procedures in
             the lower half of the face for 1 month.

          -  Understands and accepts the obligation to present for all scheduled follow-up visits
             and is logistically able to meet all study requirements.

          -  Has approximately symmetrical nasolabial folds.

        Exclusion Criteria:

          -  Has received any type of treatment or procedures including surgery in the nasolabial
             folds.

          -  Has received neurotoxins in the lower half of the face in the past 6 months.

          -  Has received hyaluronic acid, calcium hydroxylapatite (CaHA) or collagen injections in
             the lower half of the face within past 1 ½ years.

          -  Has received polylactic acid, polymethyl methacrylate (PMMA), silicone or any other
             permanent filler in the lower half of the face.

          -  Has nasolabial folds that are too severe to be corrected in one treatment session.

          -  Has a history of chronic or recurrent infection or inflammation that would preclude
             participation in the study.

          -  Has a known bleeding disorder or is receiving medication that will likely increase the
             risk of bleeding.

          -  Is female and of child bearing potential and is pregnant or not using acceptable
             method of birth control.

          -  Has had any history of hypersensitivity to Lidocaine or anesthetics of the amide type.

          -  Has a history of anaphylaxis or multiple severe allergies.

          -  Has received any investigational product within 30 days prior to study enrollment or
             is planning to participate in another investigation during the course of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marmur E, Green L, Busso M. Controlled, randomized study of pain levels in subjects treated with calcium hydroxylapatite premixed with lidocaine for correction of nasolabial folds. Dermatol Surg. 2010 Mar;36(3):309-15. doi: 10.1111/j.1524-4725.2009.01435.x. Epub 2010 Jan 19.</citation>
    <PMID>20100272</PMID>
  </results_reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2009</study_first_submitted>
  <study_first_submitted_qc>November 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2009</study_first_posted>
  <results_first_submitted>December 3, 2009</results_first_submitted>
  <results_first_submitted_qc>January 14, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 15, 2010</results_first_posted>
  <last_update_submitted>April 19, 2013</last_update_submitted>
  <last_update_submitted_qc>April 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe wrinkles and folds such as nasolabial folds</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiesse® Mixed With Lidocaine &amp; Radiesse® Without Lidocaine</title>
          <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier containing 2% lidocaine hydrochloride (HCl) and Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl). The same 50 participants received both the treatment device and the control device at the same time (left and right sides of face).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiesse® Mixed With Lidocaine and Radiesse® Without Lidocaine</title>
          <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier containing 2% lidocaine hydrochloride (HCl) and Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain)</title>
        <description>Assessment of difference in pain score in the Radiesse Dermal Filler Mixed with Lidocaine nasolabial fold v. the Radiesse Dermal Filler without Lidocaine nasolabial fold using a 10-cm visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
        <time_frame>Immediately after injection (Time 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiesse® Mixed With Lidocaine</title>
            <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier containing 2% lidocaine hydrochloride (HCl)</description>
          </group>
          <group group_id="O2">
            <title>Radiesse® Without Lidocaine</title>
            <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Pain Score Using a 10-cm Visual Analog Pain Scale (1 = no Pain, 10 = Very Severe Pain)</title>
          <description>Assessment of difference in pain score in the Radiesse Dermal Filler Mixed with Lidocaine nasolabial fold v. the Radiesse Dermal Filler without Lidocaine nasolabial fold using a 10-cm visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.8" spread="1.9"/>
                    <measurement group_id="O2" value="6.6" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patients With Clinically Significant Reduction in Pain</title>
        <description>Assessment of clinical significance of pain reduction in the Radiesse Injectable Dermal Filler Mixed with Lidocaine nasolabial fold v. Radiesse Injectable Dermal Filler without Lidocaine nasolabial fold defined as number of participants with &gt;/= 2cm difference on a visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
        <time_frame>Immediately after injection (Time 0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiesse® Mixed With Lidocaine</title>
            <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier containing 2% lidocaine hydrochloride (HCl)</description>
          </group>
          <group group_id="O2">
            <title>Radiesse® Without Lidocaine</title>
            <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)</description>
          </group>
        </group_list>
        <measure>
          <title>Patients With Clinically Significant Reduction in Pain</title>
          <description>Assessment of clinical significance of pain reduction in the Radiesse Injectable Dermal Filler Mixed with Lidocaine nasolabial fold v. Radiesse Injectable Dermal Filler without Lidocaine nasolabial fold defined as number of participants with &gt;/= 2cm difference on a visual analog pain scale (1 = no pain, 10 = very severe pain).</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Radiesse® Mixed With Lidocaine</title>
          <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier containing 2% lidocaine hydrochloride (HCl)</description>
        </group>
        <group group_id="E2">
          <title>Radiesse® Without Lidocaine</title>
          <description>Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="26" subjects_affected="25" subjects_at_risk="50"/>
                <counts group_id="E2" events="25" subjects_affected="25" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="21" subjects_at_risk="50"/>
                <counts group_id="E2" events="25" subjects_affected="23" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Redness</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="50"/>
                <counts group_id="E2" events="32" subjects_affected="30" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="47" subjects_affected="44" subjects_at_risk="50"/>
                <counts group_id="E2" events="44" subjects_affected="42" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor reserves right to review/comment on any manuscript for publication/presentation presenting data from the trial. No manuscript may be submitted for publication without prior review. Investigator agrees to accommodate reasonable requests to protect propriety rights/interests. Investigator must ensure accuracy of results. Investigator shall grant Sponsor right to reproduce/translate/use all copyrighted material from study publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merz Aesthetics, Inc.</name_or_title>
      <organization>Merz Aesthetics, Inc.</organization>
      <phone>650-286-4041</phone>
      <email>clinicaltrials@merzaesthetics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

